I don't find that displeasing, @Wasabibarako, as much as the not knowing what the plans are for all our OmniCAR trials. If pursuing allogeneic cell manufacturing is deemed to be the most logical and advanced way to proceed in conquering AML, then kudos to our scientific team for making that decision. Car-T trials have failed against AML to date for reasons PTX can and, hopefully, will tackle with success. We still have plenty in the pipeline to please investors on other fronts when news starts to flow.
